Mitochondrial Peptides MOTS-c and Humanin in Cardiac Repair and SICM

Research brief

Mitochondria-derived peptides, including MOTS-c and Humanin, exhibit significant potential in cardiac repair and sepsis-induced cardiomyopathy (SICM) by modulating metabolic and inflammatory responses. MOTS-c, in particular, supports metabolic reprogramming in myocardial infarction recovery [Li et al., 2027], while Humanin may aid prognosis in chronic heart failure [Li CY et al., 2026].

Key findings

• MOTS-c forms a hydrogel for cardiac repair by facilitating metabolic reprogramming in myocardial infarction [Li et al., 2027]. • Humanin's ratio to CRP aids risk stratification in chronic heart failure, enhancing patient management [Li CY et al., 2026]. • Mitokines, including MOTS-c and Humanin, provide insights into cardiovascular stress adaptation [Kurian, 2026]. • SS-31 peptide targets mitochondrial oxidative stress, demonstrating potential in ameliorating TBI and RA [Li W et al., 2026; Lu et al., 2026].

Detailed research context

Introduction

Mitochondria-derived peptides (MDPs) such as MOTS-c, Humanin, and SS-31 are gaining attention for their roles in cardiac repair and stress resilience. These peptides are part of a growing field of research focusing on mitochondrial dysfunction and its systemic implications.

MOTS-c in Cardiac Repair

MOTS-c, a mitochondria-derived peptide, is pivotal in myocardial infarction (MI) recovery. Li et al. (2027) describe a strategy using MOTS-c integrated into a hydrogel (MQ gel @Mito) to deliver viable mitochondria for cardiac repair after MI. This formulation enhances macrophage metabolic reprogramming, which attenuates the inflammatory response and bolsters oxidative phosphorylation, thereby reducing cardiac damage.

Humanin and Chronic Heart Failure

The Humanin/CRP ratio has been investigated as a prognostic tool in patients with acute exacerbations of chronic heart failure (CHF) [Li CY et al., 2026]. Humanin is associated with cardioprotective roles, and this ratio may serve as a predictive biomarker for cardiovascular events, potentially guiding therapeutic decision-making.

Mitokines: A Broader Perspective

Mitokines, including MOTS-c and Humanin, communicate mitochondrial stress and aid in the systemic response to cardiovascular disease, as reviewed by Kurian (2026). Their role underlines the complex signaling mechanisms that support cellular and tissue adaptations during metabolic stress.

SS-31: Mitigating Mitochondrial Oxidative Stress

SS-31, a mitochondrial-targeting peptide, has shown efficacy in reducing oxidative stress and inflammation in conditions like traumatic brain injury and rheumatoid arthritis [Li W et al., 2026; Lu et al., 2026]. By targeting mitochondrial dysfunction, SS-31 can aid in mitochondrial repair and cytokine modulation.

Challenges and Future Directions

While the therapeutic potential of these peptides is compelling, challenges such as delivery mechanisms, biomarker specificity, and pharmacokinetic profiles need resolution. The clinical translation of MOTS-c and Humanin remains limited by insufficient disease-specific mechanistic validation [Zhao et al., 2026].

Future research should explore the precise molecular pathways mediated by these peptides in diverse conditions and refine their integration into therapeutic regimes. Optimizing delivery systems and confirming mechanistic pathways could elevate their clinical applicability.

These insights bolster the therapeutic promise of MDPs and lay the groundwork for further exploration into their potential benefits in treating cardiac and systemic pathologies.

Source method

This research briefing is based on the verified PubMed records linked in the References & Citations section below.